{"filing":{"accession_number":"0001384101-26-000049","cik":"0001384101","ticker":"VCYT","company_name":"VERACYTE, INC.","form":"8-K","filing_date":"2026-09-14","report_date":"2026-09-10","primary_document":"vcyt-20260910.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1384101/000138410126000049/vcyt-20260910.htm"},"events":[{"id":33265,"run_id":30586,"accession_number":"0001384101-26-000049","anchor_item_number":"2.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"Veracyte completed the acquisition of Convergent Genomics on September 14, 2026, for $150 million in upfront cash consideration plus up to $30 million in milestone-based payments. The transaction expands Veracyte's urology diagnostics portfolio with the UroAmp urinary tumor DNA testing platform, representing a material strategic expansion into bladder cancer diagnostics.","company_name":"VERACYTE, INC.","ticker":"VCYT","filing_date":"2026-09-14","form":"8-K","submitted_at":null,"items":[{"id":36661,"accession_number":"0001384101-26-000049","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Veracyte completed the acquisition of Convergent Genomics on September 14, 2026, pursuant to a Merger Agreement signed September 10, 2026. The transaction involved $150 million in upfront cash consideration plus up to $30 million in milestone-based payments. This is a material acquisition of a genomic diagnostics company that expands Veracyte's urology diagnostics portfolio with the UroAmp urinary tumor DNA testing platform, clearly constituting a material acquisition under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T20:09:13.561773+00:00","company_name":"","ticker":null,"filing_date":""},{"id":36662,"accession_number":"0001384101-26-000049","item_number":"2.01","item_title":"Completion of Acquisition or Disposition of Assets.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Veracyte completed its acquisition of Convergent Genomics on September 14, 2026, for $150 million upfront plus up to $30 million in milestone-based consideration. This is a material acquisition that expands Veracyte's urology diagnostics portfolio with the UroAmp urinary tumor DNA testing platform, representing a strategic expansion into bladder cancer diagnostics. The transaction directly falls under Item 2.01 (Completion of Acquisition or Disposition of Assets) and would materially affect investor assessment of the company's product portfolio and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T20:09:13.561773+00:00","company_name":"","ticker":null,"filing_date":""},{"id":36663,"accession_number":"0001384101-26-000049","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Veracyte announced the completion of its acquisition of Convergent Genomics on September 14, 2026, with $150 million in upfront cash consideration and up to $30 million in milestone-based payments. The acquisition adds the UroAmp urinary tumor DNA testing platform to Veracyte's urology diagnostics portfolio, representing a material strategic expansion into a new diagnostic capability for bladder cancer care. This is a completed material acquisition disclosed via press release under Item 7.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T20:09:13.561773+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36661,"accession_number":"0001384101-26-000049","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Veracyte completed the acquisition of Convergent Genomics on September 14, 2026, pursuant to a Merger Agreement signed September 10, 2026. The transaction involved $150 million in upfront cash consideration plus up to $30 million in milestone-based payments. This is a material acquisition of a genomic diagnostics company that expands Veracyte's urology diagnostics portfolio with the UroAmp urinary tumor DNA testing platform, clearly constituting a material acquisition under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T20:09:13.561773+00:00","company_name":"VERACYTE, INC.","ticker":"VCYT","filing_date":"2026-09-14"},{"id":36662,"accession_number":"0001384101-26-000049","item_number":"2.01","item_title":"Completion of Acquisition or Disposition of Assets.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Veracyte completed its acquisition of Convergent Genomics on September 14, 2026, for $150 million upfront plus up to $30 million in milestone-based consideration. This is a material acquisition that expands Veracyte's urology diagnostics portfolio with the UroAmp urinary tumor DNA testing platform, representing a strategic expansion into bladder cancer diagnostics. The transaction directly falls under Item 2.01 (Completion of Acquisition or Disposition of Assets) and would materially affect investor assessment of the company's product portfolio and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T20:09:13.561773+00:00","company_name":"VERACYTE, INC.","ticker":"VCYT","filing_date":"2026-09-14"},{"id":36663,"accession_number":"0001384101-26-000049","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Veracyte announced the completion of its acquisition of Convergent Genomics on September 14, 2026, with $150 million in upfront cash consideration and up to $30 million in milestone-based payments. The acquisition adds the UroAmp urinary tumor DNA testing platform to Veracyte's urology diagnostics portfolio, representing a material strategic expansion into a new diagnostic capability for bladder cancer care. This is a completed material acquisition disclosed via press release under Item 7.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T20:09:13.561773+00:00","company_name":"VERACYTE, INC.","ticker":"VCYT","filing_date":"2026-09-14"}]}